A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Inclusion Criteria:

• Patient with eosinophilic asthma who completed the treatment period of a double-blind,
placebo controlled sc reslizumab study (Study C38072-AS-30025 or C38072-AS-30027)

~~ Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

- Patient has received any reslizumab administration in any previous clinical trial
other than Studies C38072-AS-30025 and C38072-AS-30027.

- The patient has any clinically significant, uncontrolled medical condition

- The patient has another confounding underlying lung disorder

- The patient has a known/diagnosed hypereosinophilic syndrome.

- The patient has a diagnosis of malignancy within 5 years of the screening visit,
except for treated and cured non-melanoma skin cancers.

- The patient is a pregnant or lactating woman

- The patient is a current smoker (ie, has smoked within the last 6 months before
screening) or has a smoking history ≥10 pack-years.

- The patient is currently using any systemic immunosuppressive or immunomodulatory
agents other than OCS

- The patient has a history of allergic reaction or hypersensitivity to any component of
the study drug.

- The patient has a history of an immunodeficiency disorder including human
immunodeficiency virus (HIV).

- Additional criteria apply, please contact the investigator for more information